TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma
Status:
Recruiting
Trial end date:
2024-03-20
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-cohort study to investigate safety, anti-tumor activity of the
monoclonal antibody BGB A317 in combination with Anlotinib and standard chemotherapy as
first-line treatment in Gastric, or Gastroesophageal Junction Carcinoma. The study includes a
screening (up to 28 days), treatment (until disease progression, intolerable toxicity, or
treatment withdrawal for another reason), safety follow-up (up to 30 days following last
study drug treatment), and survival follow-up phase.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University